To ask the Scottish Executive what the rate was of MRSA bloodstream infections as a proportion of all staphylococcus aureus bloodstream infections in the most recent year for which figures are available and what comparative information it has for (a) Norway, (b) Denmark, (c) Sweden and (d) Finland.
The following table sets out the information requested:
Proportion of Antibiotic Non-Susceptible Staphylococcus Aureus Isolates
Country | |
Scotland | 42% |
Norway | <1% |
Denmark | 2% |
Sweden | <1% |
Finland | 3% |
Note: The figures in the table should be treated with some caution. For example, the surveillance systems used to compile the data for the Scandinavian countries above are derived from the European Antimicrobial Resistance Surveillance Scheme (EARSS). Health Protection Scotland, who collect the data for NHSScotland, uses the UK definition of 14 day episodes while EARSS records one episode per quarter.
Consequently, the surveillance system used in Scotland may result in a patient who experiences more than one bacteraemic episode per quarter being counted for each episode, whereas the EARSS definition used by the other countries in the table means that each of their patients is counted only once during a quarter, even if they have more than one bacteraemic episode per quarter.
It is encouraging that the most recent “ but as yet unpublished - results for Scotland from HPS data for the last calendar year indicate that the Scotland figure for the proportion of antibiotic non-susceptible Staphylococcus aureus isolates has reduced considerably to 26%.